Kelly Arnold is an Associate Professor in the Department of Biomedical Engineering at the University of Michigan. Her research integrates systems engineering principles with immunology to investigate variability in immune responses across infection, vaccination, and injury, with a focus on computational modeling and clinical translation. Research Focus Systems-level immune response modeling Vaccination and antibody functionality Vaginal microbiome-host interactions Chronic lung disease progression Computational serology and proteomics Recent Work Her 2025 studies examine SARS-CoV-2 vaccination responses in cancer patients and computational frameworks for vaginal probiotics. Earlier works (2024-2007) span COPD progression, lupus fibrosis, HIV susceptibility, and tissue engineering for fertility preservation. Methodologies include proteomic profiling, network modeling, and microfluidic systems.
Dr. Karen Anderson is a Professor at Arizona State University (ASU), affiliated with the School of Life Sciences, the Biodesign Center for Personalized Diagnostics, and the College of Health Solutions. Her research focuses on tumor biology and immune system interactions in cancer, particularly developing biomarkers for early detection of cancers like breast, ovarian, pancreatic, and HPV-related cancers. She employs molecular techniques such as protein arrays, next-gen sequencing, and functional genomics to identify therapeutic targets and vaccine candidates. Education: Ph.D. in Microbiology and Immunology (Duke University), M.D. from Duke University School of Medicine, and B.A. in Chemistry (University of Virginia). Research interests include cancer immunotherapy, autoantibody profiling, and translational applications of proteomics. Key achievements include pioneering autoantibody-based biomarker assays and investigating HPV serology in head and neck cancers. Awards include the Health Care Heroes Award and recognition as one of Arizona's Most Influential Women. Teaching responsibilities include courses on research techniques and honors thesis supervision. Grants span biomarker validation, cancer genomics, and point-of-care diagnostics. Active in professional service, including roles in grant review panels and public health initiatives.
Ben Cosgrove is an Associate Professor in the Meinig School of Biomedical Engineering at Cornell University, serving as Director of Graduate Studies. His research focuses on systems bioengineering approaches to understand muscle stem cell dysfunction in aging and disease. He leads the Cosgrove Lab, a multidisciplinary group integrating biomedical engineering, stem cell biology, and systems biology to study microenvironmental signaling in muscle regeneration. His work includes developing biomimetic microenvironments for stem cell manufacturing and improving regenerative medicine therapies. Dr. Cosgrove holds a B.Eng. from the University of Minnesota (2003) and a Ph.D. in Bioengineering from MIT (2009). Postdoctoral training at Stanford University (with Dr. Helen Blau) followed. His research is supported by NIH grants (including R01, R21), the Glenn Medical Research Foundation, and others. He has been recognized with awards such as the BMES Graduate Research Award (2008), Rising Star Award (2015), and Swanson Teaching Excellence Award (2019). Research interests span bioengineering, biomechanics, computational science, and systems biology. His lab's innovations include spatial transcriptomic mapping and high-yield stem cell expansion platforms. Current projects aim to decode stem cell-niche interactions to treat muscle degeneration and aging. Grants: NIH K99/R00, R01, R21; Glenn Medical Research Foundation Labs/Teams: Cosgrove Lab (Cornell University) Future Work: Expanding applications of spatial transcriptomics and engineering regenerative therapies for muscle diseases
Angelica Lindén Hirschberg is a Professor of Obstetrics and Gynecology (specializing in reproductive medicine) at Karolinska Institutet and a Senior Consultant in gynecological endocrinology at Karolinska University Hospital. She holds dual roles in academic leadership and clinical practice, focusing on disorders of reproductive function, endocrine-metabolic dysfunction, and hormonal conditions in women. Her affiliations include the Department of Women’s and Children’s Health, Reproductive Endocrinology and Metabolism Research Group, and the Division for Neonatology, Obstetrics, Gynaecology, and Reproductive Health. Education and Career: MD (Karolinska Institutet, 1984) PhD (Karolinska Institutet, 1989) Professor in Obstetrics and Gynecology (2007) Board member of international societies (ISGE, EMAS) Research Focus: Her translational research spans PCOS, obesity-related reproductive dysfunction, premature ovarian insufficiency, and disorders of sex development. Projects include hormonal impacts on athletic performance, immune therapy for ovarian dysfunction, and endometrial cell biology. Collaborations involve national/international networks and clinical trials (e.g., PROBES trial). Publications: Recent work emphasizes PCOS pathophysiology, menopausal health, and hormonal interventions in athletes. Key trends include single-cell profiling of endometrium, immunomodulatory therapies for POI, and non-hormonal treatments for vasomotor symptoms. Awards: King’s Seraphim Medal (2018) 2016 Grand Prize in Sport Science Appointed Royal Gynecologist (2009) Teaching and Mentorship: Coordinates courses on reproductive endocrinology, supervises PhD students (e.g., Esin Ylmaz), and chairs the PhD Study Director at her department. Authored over 25 book chapters on women’s health and sports medicine. Grants and Labs: Secured Swedish Research Council funding for POI trials. Her lab integrates experimental (Bioclinicum) and clinical (Women’s Health Research Unit) research.
Jude M. Phillip, PhD, is an Assistant Professor in the Departments of Biomedical Engineering and Chemical and Biomolecular Engineering at Johns Hopkins University. His research integrates engineering principles with aging and cancer biology to develop cell-based biomarkers and mechanistic insights into age-related diseases. He leads the Phillip tiME Lab, which focuses on aging dynamics, tumor microenvironment interactions, and translational technologies. Education : PhD, Chemical and Biomolecular Engineering, Johns Hopkins University, 2015 Postdoctoral Research, Melnick/Cerchietti Labs, Weill Cornell Medicine, 2016-2020 B.Eng, Chemical Engineering, City College of New York, 2010 Research Interests : Dr. Phillip’s work spans aging mechanisms, cancer biology, and mechanobiology. Key areas include: Cell-based biomarkers for aging and disease Scale-dependent aging pathways Lymphoma tumor-immune microenvironment (tiME) Single-cell profiling of senescence subtypes ECM mechanoregulation of stem cell fate His lab employs longitudinal cell profiling, data science, and clinical measures to bridge biological aging research with translational medicine. Recent Highlights : 2025: NIH R35 MIRA Award for lymphoma microenvironment research 2024: Johns Hopkins Catalyst Award for aging biomarker studies 2023: AFAR-Glenn Foundation Award for senescence subtype classification Lab & Collaborations : The Phillip Lab collaborates with the Institute for NanoBioTechnology and maintains a living patient-derived tumor biorepository for lymphoma studies. Current projects include ovarian aging organoid models and immune-mechanical interactions in cancer progression.
Dr. Alison Holloway is a Professor at McMaster University's Faculty of Health Sciences, specializing in environmental toxicology and reproductive health. Her research focuses on the effects of environmental contaminants (e.g., oil sands pollutants, pesticides, endocrine disruptors) on maternal and child health, metabolic disorders, and developmental outcomes. She has conducted studies on naphthenic acids, synthetic food additives, and maternal exposure to pharmaceuticals like fluoxetine. Key research areas include: Environmental contaminants' impact on reproductive systems and placental function Metabolic disturbances caused by chemical exposures during critical developmental windows Neurobehavioral and gastrointestinal effects of prenatal drug exposure Assessment of urban air pollution on in vitro fertilization (IVF) success rates Her recent work highlights the role of the tryptophan-kynurenine pathway as a biomarker of environmental stress and the obesogenic effects of bisphenol analogs and food additives. Collaborations involve interdisciplinary teams addressing environmental health, with studies published in high-impact toxicology and public health journals. Dr. Holloway's research has informed policies on chemical safety and maternal health, emphasizing cross-species markers for organismal health and risk assessment of emerging contaminants like cannabis derivatives.
Feyruz V. Rassool is a Professor at the University of Maryland School of Medicine, with primary appointment in Radiation Oncology. She serves as Co-director of the Experimental Therapeutics Program at the University of Maryland Greenebaum Comprehensive Cancer Center (UMGCCC) and holds an adjunct Associate Professor position at VARI’s Center for Epigenetics. Her research focuses on DNA damage/repair pathways in cancer, particularly their therapeutic exploitation through PARP and DNMT inhibitors. Education: B.Sc. in Human Genetics (1983, University College London), Ph.D. in Biological Sciences (1990, Royal Postgraduate Medical School) Postdoctoral Training: University of Chicago (1990-1994) Her work explores the intersection of DNA repair , epigenetics , and mitochondrial dysfunction to develop novel therapies for breast, ovarian, lung, and leukemias. Key projects include STING-dependent interferon signaling , pathogen mimicry in cancer cells, and metastasis suppression through PARPi/epigenetic combinations. Dr. Rassool is part of the SU2C Epigenetics Dream Team and has secured multiple grants from NCI, NIH, and the Adelson Medical Research Foundation. Her recent preclinical studies with PARP/DNMT inhibitors are being translated into Phase I/II trials for AML and TNBC. Scientific Awards Ziskin Award (2012) NCI-SPORE Grant Co-Leader NIH/NCI P30 CA134274 Support Grant She has mentored 13 PhD/postgraduate researchers and collaborates on clinical trials with Pfizer, VARI-SU2C, and ASTRO. Her lab employs techniques like DNA repair assays , RNAseq , and mouse xenograft models to investigate mechanisms of action for epigenetic drugs.
Carlos Salomon Gallo is a Professor and NHMRC Investigator Fellow (EL2) at The University of Queensland's Centre for Clinical Research, affiliated with the School of Biomedical Sciences. He directs the Centre for Extracellular Vesicle Nanomedicine and leads the Exosome Biology Laboratory. A globally recognized key opinion leader in extracellular vesicles (ranked 3rd worldwide by Expertscape), his research focuses on EV biology for diagnostic and therapeutic applications in ovarian cancer, gestational diabetes, preeclampsia, and other obstetrical syndromes. His research integrates proteomics (SWATH-MS), miRNA analysis, and advanced isolation techniques to develop liquid biopsies. Core interests include: EV biomarker discovery and validation for early disease detection. Mechanisms of EV-mediated signaling in metabolic and oncological pathologies. Engineering EVs for targeted drug delivery and CRISPR-Cas therapeutics. Clinical translation of EV-based diagnostics (IVDs) and therapeutics. Analysis of his recent articles reveals a dominant focus on EV profiling in pregnancy complications (gestational diabetes, preeclampsia) and oncology (ovarian cancer), utilizing multi-omics approaches. Key trends include developing high-sensitivity EV biosensors, understanding hypoxia-induced EV signaling, and exploring 3D models for EV research. He has received significant recognition, including: NHMRC Emerging Leadership Fellow NHMRC Investigator Fellow (EL2) He leads the Exosome Biology Laboratory and the UQ Centre for Extracellular Vesicle Nanomedicine, fostering cross-disciplinary collaboration. His work involves extensive national and international partnerships, evidenced by leadership roles in the Centre for Clinical Diagnostics and over 20 invited international talks in 5 years. He actively mentors HDR students and contributes to global EV research standards (MISEV2023).
Jessica A. Mong, PhD , is a Professor in the Department of Pharmacology & Physiology at the University of Maryland School of Medicine , where she also serves as Assistant Dean for Graduate & Post-Doctoral Studies and Director of Graduate Education for the Program in Neuroscience. Her research focuses on the neuroendocrine mechanisms underlying sex differences in sleep circuitry and the estrogenic modulation of sleep-wake cycles. Primary Appointment: Pharmacology & Physiology Administrative Title: Assistant Dean for Graduate & Post-Doctoral Studies Laboratory Director: Program in Neuroscience Research Interests: Dr. Mong's work investigates how ovarian steroids influence sleep-wake behavior through sexually differentiated neuroanatomical substrates. Key areas include: Mechanisms of estrogenic modulation in the median preoptic nucleus (MnPN) Developmental programming of sex differences in sleep sensitivity Translational studies using rodent and nonhuman primate models of menopause Functional significance of hormonal influences on sleep quality and recovery Scientific Trends: Her recent publications (2023-2025) emphasize: Role of KCNMA1 channelopathy in sleep regulation Adenosinergic signaling in MnPN Translational menopause models Estrogen's protective effects against noise-induced hearing loss Sex-dependent responses to kynurenine pathway challenges Awards & Appointments: NIH BIRCWH Scholar (Building Interdisciplinary Research Careers in Women's Health) Co-Chair, Society for Women’s Health Research Interdisciplinary Research Network on Sex-Differences in Sleep Health NIH/NHLBI R01 HL129138 grant recipient Education & Training: B.S., Biology, Gettysburg College (1987-1991) Ph.D., Neuropharmacology, University of Maryland Baltimore (1994-2000) NIH Postdoctoral Fellowship in Endocrinology, Rockefeller University (2000-2003)
Fuchsia Howard, PhD, RN serves as an Associate Professor and PhD Coordinator at the University of British Columbia School of Nursing. Her office is located at T201 2211 Wesbrook Mall, Vancouver, BC V6T2B5, with contact via phone (1-604-822-4372) and email (fuchsia.howard@ubc.ca). Her research spans oncology nursing, reproductive health, critical care survivorship, and health equity . She investigates fertility preservation for cancer patients, endometriosis-associated dyspareunia management, and digital health interventions for sexual health. Her work emphasizes patient-reported and family-reported outcomes , particularly in chronic disease management and post-ICU recovery. Current projects address social determinants of health in critical illness survivorship and destigmatizing design for sexual health technologies. Her recent publications (2023-2025) demonstrate strong focus on Patient-centered outcome measures in oncology and gynecology Digital resource development for endometriosis and fertility challenges Family caregiver roles in critical illness recovery Health equity in Canadian cancer care systems Key methodologies include qualitative studies, scoping reviews, and mixed-methods approaches. As PhD Coordinator, she guides nursing doctoral candidates though specific students aren't listed in available materials. Her work connects with clinical practice through collaborations with BC Cancer and UBC-affiliated hospitals.
Sophia Lunt is a Professor in the Department of Biochemistry & Molecular Biology and Chemical Engineering & Materials Science at Michigan State University , where she has been since 2015 (Assistant Professor 2015-2021, Associate Professor 2021-2025, Professor 2025-present). She leads the Lunt Lab , focusing on cancer metabolism , particularly metabolic reprogramming in tumor proliferation, heterogeneity, and metastasis . Her work combines mass spectrometry , genetic cancer models , cell biology , and fluorescent agents to develop targeted cancer therapies . Ph.D. (2010) & B.S. (2005) in Chemistry Postdoctoral Fellow at MIT (2010-2015) NSF CAREER awardee (2019) 20+ peer-reviewed publications since 2007 Research Focus : Cancer metabolism (Warburg effect, PHGDH heterogeneity, TIGAR regulation) Photodynamic therapy (counterion-tuned agents, metal halide nanoclusters) Metabolomics (tumor-immune interactions, microbiome effects) Selected Scientific Awards : 2022 MSU College of Natural Science Teacher-Scholar Award 2022 MSU BMB Teaching Award 2020 MANA Young Investigator Award 2019 NSF CAREER & METAvivor Early Career Investigator Awards Her teaching includes BMB 101: Frontiers in Biochemistry (curriculum overhaul for freshman success) and BMB 461: Advanced Biochemistry I , covering metabolic regulation and pathways.
Kalyani Nair is a Professor in the Mechanical Engineering Department at Bradley University's Caterpillar College of Engineering & Technology, based in the Business and Engineering Convergence Center (BEC 3265). She can be contacted at knair@bradley.edu or (309) 677-4562. Her educational background includes: Ph.D. in Mechanical Engineering from Drexel University B.S. in Biomedical Engineering from Cochin University Dr. Nair's research focuses on biomedical engineering with expertise in biomechanics and tissue engineering . She investigates myofascial tissue mechanics in inflammatory conditions like ankylosing spondylitis, develops medical devices for spinal pathologies, and creates biomaterial scaffolds for tissue regeneration. Her work bridges engineering principles with clinical applications through techniques like myotonometry, electromyography, and computational modeling. Analysis of her recent publications (2015-2025) reveals persistent themes in musculoskeletal biomechanics, particularly spinal disorders and myofascial tissue properties, alongside tissue engineering for tendon regeneration and cancer models. Key trends include quantification of tissue mechanical properties, medical device innovation for pediatric neurosurgery, and scaffold optimization for regenerative medicine. Within the department, Dr. Nair serves as Coordinator of the Biomedical Concentration and sits on the Committee on the Use of Human Subjects in Research. She teaches courses spanning engineering design (ME 102), biomedical fundamentals (ME 280), CAD applications (ME 448, ME 648), and advanced topics in biomechanics (ME 580) and tissue engineering (ME 591).
Dr. Michael D. Burton is an **Associate Professor** and **Eugene McDermott Distinguished Professor** in the Department of Neuroscience at the University of Texas at Dallas (UT Dallas), affiliated with the **School of Behavioral and Brain Sciences**. He is a founding member of the **Center for Advanced Pain Studies (CAPS)** and holds roles in the **Center for Vital Longevity (CVL)**. His research focuses on neuroimmunology, pain mechanisms, and metabolic disorders, emphasizing how immune-nervous system interactions influence chronic pain, depression, anxiety, and aging-related conditions. Dr. Burton’s work bridges preclinical and translational research, using rodent models and human clinical samples. Education: PhD in Animal Science (Immunophysiology and Behavior), University of Illinois at Urbana-Champaign (2012) B.S. in Animal Science and Biotechnology, University of Illinois at Urbana-Champaign (2006) Postdoc in Pain Neurobiology, UT Dallas (2017) Postdoc in Diabetes/Metabolism Research, UT Southwestern Medical Center (2015) Research Interests: Dr. Burton investigates how peripheral stimuli (diet, alcohol, immune activation) affect pain and behavior through neuroimmune pathways. Key areas include: Sex differences in pain sensitivity and neuroinflammation Risk factors for chronic pain (e.g., high-fat diets, aging) Neuroimmune biomarkers for pain and delirium Development of non-opioid analgesics (e.g., cannabinoids) Awards: 2024 ROAR Research Award, UT Dallas 2023 Eugene McDermott Distinguished Professorship 2022 SFNova/Rising Star (Society for Neuroscience) 2019 Mitchell Max Award for Pain Research Grants & Leadership:** Co-Director, **Enhancing Neuroscience Undergraduate Research Experiences (ENSURE)** program ($900K grant) NIH R35, R21 grants (pain and metabolism) Editorial roles: *Neurobiology of Pain*, *Journal of Neuroinflammation*, and others Labs & Teams:** Neuroimmunology and Behavior Lab (UT Dallas) Member, NIH Pain Consortium and Endocrine Society’s Basic Science Group
Marla Lujan serves as Associate Professor in the Division of Nutritional Sciences at Cornell University's College of Human Ecology, where she leads the Lujan Laboratory (Cornell Ovary Lab) investigating the intersection of nutrition, metabolism, and women's reproductive health. Her educational background includes a Master of Science and Doctor of Philosophy in Physiology from Queen's University (Kingston, Ontario), with postdoctoral training in Obstetrics, Gynecology and Reproductive Sciences at the University of Saskatchewan. Current research focuses on elucidating pathophysiological mechanisms causing amenorrhea and PCOS through high-resolution ovarian ultrasonography to characterize follicle development and morphology across the reproductive lifespan. Key research themes include: Metabolic drivers of ovulatory dysfunction in PCOS Adolescent ovarian development trajectories in PCOS risk Artificial intelligence applications for ultrasound-based PCOS diagnosis Dietary interventions for improving ovulatory function Cross-disciplinary assessments of healthcare experiences in women with endocrine disruptions Dr. Lujan actively mentors graduate students including Avery Zhang (hypocaloric dietary interventions for PCOS), Samiha Azgar (adolescent ovarian morphology transitions), and Abbey Kampel (ovarian phenotyping in PCOS), while collaborating with Weill Cornell and Children's Mercy Hospital on multi-site studies. Her laboratory recruits participants for ongoing research including the Adolescent Ovary Study and leverages archival ultrasound data for AI diagnostics development. The Lujan Laboratory team comprises graduate students, undergraduate researchers, and postdoctoral trainees working at the intersection of nutritional science, reproductive endocrinology, and imaging technology to advance diagnostic and therapeutic approaches for women's reproductive health conditions.
William Newman is a Clinical Professor of Translational Genomic Medicine at the University of Manchester and Honorary Consultant at Manchester University NHS Foundation Trust. He serves as President of the European Society of Human Genetics (2024-25) and Clinical Director of the NW Genomic Medicine Service Alliance. His roles include co-leading the BRC Theme on Rare Conditions and leading the NHSE Network of Excellence in Pharmacogenetics and Medicines Optimisation. Education: BSc (hons) Experimental Immunology and Oncology MB ChB (hons) from the University of Manchester PhD in genetics from the Wellcome Trust Cell Matrix Centre MA in Healthcare Ethics and Law Research Interests: Rare Conditions : Discovery of genetic causes using next-generation sequencing, focusing on Perrault syndrome, lower urinary tract disorders, and infection-triggered neuropathies. Pharmacogenetics : Clinical implementation of genetic testing to optimize medication responses, including the PALOH study for gentamicin-induced hearing loss prevention. Lower Urinary Tract Malformations : Studies on HPSE2 and LRIG2 genes in urofacial syndrome and bladder exstrophy, supported by the MRC-NIHR Rare Disease Node (REOLUT). Genetics of Perrault Syndrome : Identification of CLPP, MRPL49, PRORP, and DAP3 genes, exploring mitochondrial dysfunction mechanisms. Spliceosomal Disorders : Investigating craniofacial syndromes like Burn McKeown syndrome using mouse and stem cell models. Key Awards: New Statesman Healthcare Positive Impact Award 2022 Times Higher Education (THE) Research Project of the Year: STEM Award 2024 Teaching and Collaborations: Established MSc in Genomic Medicine and PGCert in Clinical Genetics with international partners. Collaborates with institutions like Newcastle University, UCL, and Cambridge on rare disease projects. Leadership in European Society of Human Genetics training programs for cardiac genetics professionals. Labs and Platforms: Manchester Centre for Genomic Medicine, Manchester Regenerative Medicine Network, and the Lydia Becker Institute.
